What interventions could be utilized in order to overcome these challenges? Response to Michaeline Youngkendeh

Response to Michaeline Youngkendeh

Leukemia is a type of blood cancer caused by a breakdown in normal cellular regulation, resulting in the uncontrolled production of immature WBCs in the bone marrow. As a result, the bone marrow becomes overcrowded with immature, nonfunctional cells, and the production of other normal blood cell types decreases significantly. Acute leukemia has a sudden onset, whereas chronic leukemia has a slow onset and symptoms that last for years. Cancer most commonly occurs in stem cells or early precursor leukocyte cells in leukemia, causing excessive growth of one type of immature leukocyte. Excessive bone marrow production halts average bone marrow production, resulting in anemia, thrombocytopenia, and leukopenia.

Induction chemotherapy is a high-dose chemotherapy regimen that lasts about a week. The goal is to clear the blood of leukemia cells and return the bone marrow blast count to normal. Imatinib mesylate is the first-line treatment for chronic myelogenous leukemia (CML). This oral medication has shown to be effective in inducing remission in the early stages of CML. Hematopoietic stem cell transplantation is a standard treatment option for patients with acute leukemia who have a closely matched donor and are in remission after induction therapy.

Immune changes increase the risk of infection in leukemia patients. Even if the WBC count is average or high, these cells are immature and cannot protect the patient from infection. Acute leukemia severely limits platelet production in the bone marrow, resulting in thrombocytopenia. In response to minor trauma, the patient is at high risk for poor clotting and excessive bleeding. Induction therapy or high-dose chemotherapy for transplantation can also cause thrombocytopenia.